- Home
- LRMR vs NVCT Comparison
LRMR vs NVCT Comparison
Compare LRMR & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRMR
- NVCT
- Stock Information
- Founded
- LRMR N/A
- NVCT 2020
- Country
- LRMR United States
- NVCT United States
- Employees
- LRMR N/A
- NVCT N/A
- Industry
- LRMR Biotechnology: Pharmaceutical Preparations
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- LRMR Health Care
- NVCT Health Care
- Exchange
- LRMR Nasdaq
- NVCT Nasdaq
- Market Cap
- LRMR 191.4M
- NVCT 184.9M
- IPO Year
- LRMR N/A
- NVCT 2022
- Fundamental
- Price
- LRMR $3.09
- NVCT $7.54
- Analyst Decision
- LRMR Strong Buy
- NVCT Strong Buy
- Analyst Count
- LRMR 7
- NVCT 3
- Target Price
- LRMR $17.86
- NVCT $17.00
- AVG Volume (30 Days)
- LRMR 1.4M
- NVCT 181.9K
- Earning Date
- LRMR 08-06-2025
- NVCT 08-05-2025
- Dividend Yield
- LRMR N/A
- NVCT N/A
- EPS Growth
- LRMR N/A
- NVCT N/A
- EPS
- LRMR N/A
- NVCT N/A
- Revenue
- LRMR N/A
- NVCT N/A
- Revenue This Year
- LRMR N/A
- NVCT N/A
- Revenue Next Year
- LRMR N/A
- NVCT N/A
- P/E Ratio
- LRMR N/A
- NVCT N/A
- Revenue Growth
- LRMR N/A
- NVCT N/A
- 52 Week Low
- LRMR $1.61
- NVCT $4.44
- 52 Week High
- LRMR $11.20
- NVCT $11.80
- Technical
- Relative Strength Index (RSI)
- LRMR 60.78
- NVCT 34.18
- Support Level
- LRMR $2.81
- NVCT $7.25
- Resistance Level
- LRMR $3.19
- NVCT $7.59
- Average True Range (ATR)
- LRMR 0.30
- NVCT 0.41
- MACD
- LRMR 0.01
- NVCT -0.05
- Stochastic Oscillator
- LRMR 82.43
- NVCT 17.06
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.